<?xml version="1.0" encoding="UTF-8"?>
<ref id="B61-pharmaceuticals-13-00464">
 <label>61.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Van Swearingen</surname>
    <given-names>A.E.D.</given-names>
   </name>
   <name>
    <surname>Sambade</surname>
    <given-names>M.J.</given-names>
   </name>
   <name>
    <surname>Siegel</surname>
    <given-names>M.B.</given-names>
   </name>
   <name>
    <surname>Sud</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>McNeill</surname>
    <given-names>R.S.</given-names>
   </name>
   <name>
    <surname>Bevill</surname>
    <given-names>S.M.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Bash</surname>
    <given-names>R.E.</given-names>
   </name>
   <name>
    <surname>Mounsey</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Golitz</surname>
    <given-names>B.T.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer</article-title>
  <source>Neuro-Oncol.</source>
  <year>2017</year>
  <volume>19</volume>
  <fpage>1481</fpage>
  <lpage>1493</lpage>
  <pub-id pub-id-type="doi">10.1093/neuonc/nox052</pub-id>
  <pub-id pub-id-type="pmid">28486691</pub-id>
 </element-citation>
</ref>
